Delivering a Next Generation Platform for Antibody Drug Discovery

Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses.

In June 2018, Deerfield Management and Ablexis signed a definitive agreement under which Deerfield Management will acquire Ablexis.

Year Invested: 2009

Recent News

December 6, 2018
Ablexis Announces Licensing Agreement with Allogene Therapeutics

November 13, 2018
Ablexis Announces Progress in Its Intellectual Property on AlivaMab Mouse and Immunoglobulin Locus Engineering

November 5, 2018
Ablexis Announces Antibody Discovered Using AlivaMab Mouse Platform Enters Clinical Development

Read More News

Associated Team Members

Cary Pfeffer, M.D.